Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML

Summary

A phase 1, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).

Timeline

Start

2021-07-12

Primary completion

2023-09-06

Completion

2023-09-06

Outcome

Outcome not reported

Stopped (Business): “The decision to discontinue LAVA-051clinical trial follows a recent review of the competitive landscape that has continued to evolve (Business decision). The decision is not due to safety concerns.”

Drugs

Indications